Lamotrigine for Bipolar Depression Prevention — MRCPsych Paper B MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Lamotrigine
Lamotrigine is correct. Its UK indication specifically covers prevention of depressive episodes in adults with bipolar I disorder whose course is predominantly depressive; it is not indicated for acute depressive or manic episodes. In pivotal maintenance studies, lamotrigine delayed depressive episodes compared with placebo, whereas the difference for manic, hypomanic or mixed episodes was not statistically significant. Lithium remains NICE's first-line and most effective long-term treatment for bipolar disorder overall, so it would be correct if the question asked for general relapse prevention rather than depression-focused licensed efficacy. Quetiapine is a NICE-listed alternative when lithium is unsuitable but does not match this specific evidence profile. Valproate and carbamazepine likewise lack this depression-specific UK indication, and valproate is particularly restricted in women of childbearing potential.
Reference: Lamotrigine Milpharm 25 mg tablets, Summary of Product Characteristics, sections 4.1 and 5.1, revised 2026. https://www.medicines.org.uk/emc/product/4736/smpc